Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

30 Sept 2008

Abstract excerpt

PURPOSE: To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a small-molecule inhibitor of survivin. PATIENTS AND METHODS: Patients with advanced solid malignancies or lymphoma were treated with escalating doses of YM155 administered by 168-hour continuous intravenous infusion (CIVI). Plasma and urine samples were assayed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Cell death mechanisms and regulation
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18824702
DOI: 10.1200/jco.2008.17.2064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinPMID 18824702Read ↗

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of TemsirolimusSemantic proximity Read ↗

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read ↗

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.Semantic proximity Read ↗

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.Semantic proximity Read ↗

Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.Semantic proximity Read ↗

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.Semantic proximity Read ↗

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.Semantic proximity Read ↗

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.